Revelation Biosciences Inc. Engages in Warrant Exercises for Funding
Revelation Biosciences, Inc. (NASDAQ: REVB), a pioneering clinical-stage life sciences company, is thrilled to disclose its recent agreement regarding the immediate exercise of outstanding warrants. This move is set to generate approximately $4 million in gross proceeds. The warrants enable the holders to purchase shares of common stock, unfurling significantly for the future prospects of the company.
Details of the Warrant Exercise Agreement
Under the terms of the agreement, the exercise pertains to over 4 million shares of common stock, which were specifically issued on a recent date for $1.00 each. The company has ensured that these securities are registered with the Securities and Exchange Commission (SEC) under an effective registration statement, paving the way for a transparent and compliant transaction.
Role of Financial Advisors
To navigate this strategic financial move, Revelation has engaged Roth Capital Partners as its financial advisor. Their expertise will undoubtedly facilitate a smooth process during this critical financial maneuver.
New Warrants for Exercising Holders
As part of the agreement, holders who opted for immediate cash exercise of their existing warrants will receive new warrants, further enhancing their investment opportunities. These new Class F and Class G warrants will allow the purchase of additional common stock, with varying exercise timelines and terms of validity, ensuring holders have flexible options to maximize their investments.
Understanding the New Warrants
The Class F warrants can be exercised for up to 4 million shares, while the Class G warrants offer a more extensive opportunity for the purchase of over 6 million shares. This arrangement ensures that investors remain engaged with Revelation's ongoing initiatives and growth plans.
Commitment to Regulatory Compliance
Compliance remains a priority for Revelation, especially when embarking on such significant financial activities. The company remains committed to ensuring all new securities are subject to the relevant regulations, filing necessary documentation with the SEC after completion of the transaction. This proactive approach helps safeguard investors’ interests and adhere to legal obligations.
About Revelation Biosciences Inc.
Revelation Biosciences, Inc. stands at the forefront of innovation in the life sciences domain. By focusing on trained immunity, the company seeks to revolutionize the prevention and treatment of various diseases, harnessing its proprietary formulation, Gemini. Currently, multiple clinical programs are underway to assess Gemini’s capabilities, particularly in preventing acute kidney injury and treating chronic kidney disease.
What Lies Ahead for Revelation?
The successful exercise of these warrants signals exciting developments ahead for Revelation. With the additional capital, the company is poised to further its research and development initiatives, strengthen its position in the life sciences arena, and drive impactful healthcare innovations.
Frequently Asked Questions
What is the purpose of the warrant exercise by Revelation Biosciences?
The exercise aims to raise approximately $4 million, which will support the development of its innovative life sciences programs.
How many shares are involved in the warrant exercise?
The agreement allows the purchase of up to 4,064,040 shares of common stock at an exercise price of $1.00 per share.
Who is the financial advisor for this transaction?
Roth Capital Partners has been appointed as the financial advisor to assist in this process.
What are the new warrants provided to exercising holders?
Exercising holders will receive Class F and Class G warrants, enabling additional stock purchases under specified terms and timelines.
What does this transaction mean for the future of Revelation Biosciences?
This transaction is a significant step forward, providing Revelation with necessary funds to propel its research initiatives and enhance its product offerings in the life sciences sector.
